Publicação científica trimestral do CREMERJ

43 Tratamento do diabetes tipo 2: tendências atuais Alessandra Saldanha de Mattos Matheus Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.25-44, jan-mar 2022 38. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014; 37(8):2149-58. 39. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394 (10193):121-30. 40. Fonseca VA, Alvarado-Ruiz R, Raccah D et al. Efficacy and safety of the once daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012; 35(6):1225-31. 41. Ahren B, Galstyan G, Gautier JF et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18. 42. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373 (23):2247-57. 43. Tucker ME. FDA Approves CVD Benefit for Once-Weekly Semaglutide. Medscape Medical News. 2020 Jan 17. 44. Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375 (19):1834-44. 45. Rosenstock J, Allison D, Birkenfeld AL et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019; 321 (15):1466-80. 46. HusainM, Birkenfeld AL, Donsmark M. PIONEER 6 Investigators et al.Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019 doi:10.1056. 47. Vilsbøll T, Bain SC, Leiter LA et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018; 20: 889-897. 48. Perez-Monteverde A, Seck T, Xu L et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract. 2011; 65(9):930-8. 49. Green JB, Bethel MA, Armstrong PW et al., Effect of sitagliptin on cardio-vascular outcomes in type 2 diabetes, N Engl J Med 2015; 373: 232-242. 50. Rosenstock J, Perkovic V, Johansen OE et al., Effect of Linagliptin vs Placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, JAMA 2019; 321: 69-79. 51. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14):1317-1326. 52. Zannad F, Cannon CP, Cushman WC et al., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet 2015; 385:2067-2076. 53. https://diretriz.diabetes.org.br/doenca-renal-do-diabetes/ acessado em 23/08/2021. 54. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373 (22):2117-28. 55. Christoph Wanner C, Inzucchi SE, Lachin JM. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375:323-334. 56. Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7):644-657. 57. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380 (24):2295-306.